Targeting Notch, MYC/BRD4, Cyclin D3:CDK4/6, and the PI3K pathway are promising therapeutic targets in T-ALL, and the strong pre-clinical studies discussed above support further investigation of these drugs in clinical trials in patients with T-ALL. Here, CDK4 is linked to acute lymphoblastic leukemia.